<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01003418</url>
  </required_header>
  <id_info>
    <org_study_id>113629</org_study_id>
    <nct_id>NCT01003418</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children</brief_title>
  <official_title>Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 8 to 12 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and immunogenicity of two doses of the H1N1
      candidate vaccine administered in children aged between 8 and 12 weeks at the time of first
      vaccination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage, intensity and relationship to vaccination of solicited local and general signs and symptoms, unsolicited adverse events and serious adverse events</measure>
    <time_frame>Two weeks post-dose 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral immune response in terms of investigational vaccine HI antibodies</measure>
    <time_frame>at Visit 1 (Day 0), Visit 3 (Day 28), Visit 4 (Day 56),Visit 6 (study Month 4), Visit 7 (study Month 5) and Visit 9 (study Month 11)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral immune response in terms of investigational vaccine neutralising antibodies</measure>
    <time_frame>at Visit 1 (Day 0), Visit 3 (Day 28), Visit 4 (Day 56),Visit 6 (study Month 4), Visit 7 (study Month 5) and Visit 9 (study Month 11)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immune response to components of the routine immunisation vaccines</measure>
    <time_frame>At visit 6 (study Month 4) and/or at visit 9 (study Month 11)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage, intensity and relationship to vaccination of local and general solicited symptoms</measure>
    <time_frame>During the 7-days follow-up after each investigational vaccine administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of local and general solicited symptoms</measure>
    <time_frame>During the 7-days follow-up after each investigational vaccine administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage, intensity and relationship to vaccination of unsolicited adverse events</measure>
    <time_frame>During the 28-day follow-up after each investigational vaccine administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of MAEs, AESIs, SAEs and relationship to vaccination</measure>
    <time_frame>Throughout the study (from day 0 to Month 11)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two doses of investigational vaccine regimen according to a 0-28 day schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two doses of investigational vaccine regimen according to a 0-4 month schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine</intervention_name>
    <description>Two doses; intramuscular administration</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>InfanrixTM-IPV/Hib</intervention_name>
    <description>Routine infant immunisation vaccine, three doses administered intramuscularly</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar</intervention_name>
    <description>Routine infant immunisation vaccine, three doses administered intramuscularly</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects must satisfy ALL the following criteria at study entry:

          -  Subjects who the investigator believes that their parent(s)/Legally Acceptable
             Representative(s) (LARs) can and will comply with the requirements of the protocol

          -  Children, male or female, aged between 8 and 12 weeks at the time of first study
             vaccination.

          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject.

          -  Healthy children, as established by medical history and clinical examination when
             entering the study.

          -  Parent/LAR with access to a consistent means of telephone contact, land line or
             mobile, but NOT a pay phone or other multiple-user device.

          -  Born after a gestation period of &gt;= 36 to &lt;= 42 weeks.

        Exclusion Criteria:

        The following criteria should be checked at the time of study entry. If ANY exclusion
        criterion applies, the subject must not be included in the study:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine within 30 days preceding the first dose of the study vaccine or planned
             use during the study period.

          -  Acute disease at the time of enrolment.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination (no laboratory testing required).

          -  History of any neurological disorders or seizures.

          -  A family history of congenital or hereditary immunodeficiency.

          -  Receipt of systemic glucocorticoids within one month of study enrolment, or any other
             cytotoxic or immunosuppressive drug since birth.

          -  Administration of any vaccines within two weeks before study enrolment.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study.

          -  Previous administration of any H1N1 vaccine, of any seasonal influenza vaccine.

          -  Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis,
             Haemophilus influenzae type b, and/or Streptococcus pneumoniae with the exception of
             vaccines where the first dose can be given within the first two weeks of life
             according to the national recommendations.

          -  History of intercurrent diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus
             influenzae type b disease.

          -  Major congenital defects or serious chronic illness.

          -  Child in care.

          -  Any known or suspected allergy to any constituent of the influenza, DTPa-IPV/Hib and
             pneumococcal study vaccines; a history of anaphylactic-type reaction to consumption of
             eggs; or a history of severe adverse reaction to a previous influenza, DTPa-IPV/Hib
             and pneumococcal vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>HÃ¸nefoss</city>
        <zip>N-3515</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lierskogen</city>
        <zip>3420</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2009</study_first_submitted>
  <study_first_submitted_qc>October 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2009</study_first_posted>
  <disposition_first_submitted>December 23, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>December 23, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 30, 2010</disposition_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK2340272A</keyword>
  <keyword>H1N1 pandemic influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113629</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113629</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113629</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113629</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113629</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113629</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <pending_results>
    <submitted>March 3, 2017</submitted>
    <returned>April 13, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

